Drug Profile
SJP 0129
Alternative Names: SJP-0129Latest Information Update: 20 Feb 2019
Price :
$50
*
At a glance
- Originator Senju Pharmaceutical
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Patent ductus arteriosus
Most Recent Events
- 20 Feb 2019 Discontinued - Phase-III for Patent ductus arteriosus (In neonates) in Japan (IV)
- 28 Jul 2016 Senju Pharmaceuticals completes a phase-III trial in Patent ductus arteriosus (In neonates) in Japan (IV) (UMIN000018226)
- 07 Jul 2015 Clinical trials in Patent ductus arteriosus in Japan (IV)